ArticleNutrition & metabolism2026
Cardiometabolic health and all-cause and cause-specific mortality in the general US adult population.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiometabolic health (CMH) holds potential prognostic value for long-term outcomes, highlighting the need for simple and cost effective tools that utilize modifiable variables to identify individuals at risk of mortality. This study aims to investigate the association between a CMH score derived from the Look AHEAD trial and mortality risk in the US population.
methodsData were obtained from the National Health and Nutrition Examination Survey spanning 2005 to 2018, with mortality data linked through December 2019. The CMH score was calculated based on waist circumference, blood pressure, glomerular filtration rate, serum glycated hemoglobin, and urine albumin-to-creatinine ratio. Individuals were categorized into low (0-3), intermediate (4-5), and high (6-8) CMH groups. Multivariable Cox regression was used to explore the association between CMH score and mortality.
resultsThe analysis included 31,884 US adults (mean age 47.2 years; 48.8% male). Over a mean follow-up of 7.56 years, there were 2,997 mortality events, including 906 CVD deaths, 732 cancer deaths, and 1,359 deaths from other causes. A higher CMH score was associated with a lower risk of all-cause mortality. The adjusted hazard ratios (aHR) for all-cause mortality events were 2.17 (95% confidence interval [CI] 1.88-2.52) and 1.36 (95% CI 1.20-1.53) in the low and intermediate CMH groups, respectively, compared to the high CMH group. Similar inverse associations were observed for mortality from cardiovascular disease, cancer, and other causes.
conclusionsThe CMH score, utilizing simple and modifiable parameters, predicts the future risk of mortality in the US population. This simple and modifiable CMH scoring system offers a comprehensive assessment of cardiometabolic status and may serve as a practical tool for risk stratification in both clinical and public health settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.